NeuroSense Therapeutics publishes CEO shareholder letter on Phase 3 PrimeC plans - NRSN News | RalliesNeuroSense Therapeutics publishes CEO shareholder letter on Phase 3 PrimeC plans
N
NRSN• CEO letter outlines funding, PARAGON timing and Nasdaq compliance steps
- NeuroSense published a CEO shareholder letter outlining delays in securing funding needed to start the Phase 3 PARAGON study of PrimeC in ALS.
- FDA clearance received to initiate PARAGON; trial planned to enroll about 300 participants, mainly in the US, with timing tied to financing.
- Canada regulatory push advanced; New Drug Submission for PrimeC now targeted for December 2026 following Health Canada pre-NDS discussions.
- CEO Alon Ben-Noon cited April investments of USD 200,000 each by him and CFO Or Eisenberg, alongside an existing investor.
- Nasdaq compliance efforts include seeking more time, with a proposed reverse split authorization range of 1-for-4 to 1-for-40 if needed.
•
